Skip to main content
. 2013 Mar 6;22(14):2047–2056. doi: 10.1089/scd.2012.0615

FIG. 3.

FIG. 3.

Immunological changes in the BP-treated minipigs and bone remodeling and immunoregulation improvement after BMMSC infusion. (A) CD4+CD25+ T-cells were significantly decreased in the peripheral blood from the BP-treated groups at 24 weeks after the BP treatment compared with the untreated control group (P<0.05). (B) BP treatment also resulted in slightly reduced Foxp3+ levels in the peripheral blood at 24 weeks after BP treatment (P=0.05). (C) interleukin (IL)-17 levels in the peripheral blood in the BP-treated groups were increased compared with the untreated control group at 24 weeks after BP treatment (P<0.05). (D) The levels of γδT cells in the BP groups were significantly increased compared with the control group at 24 weeks after BP treatment (P<0.05). At 12 weeks after BMMSC transplantation, the level of CD4+CD25+ T-cells recovered (P<0.05) (E); the level of Foxp3 mRNA tended to increase in BRONJ minipigs (P<0.05) (F); and IL-17 levels were also reduced after treatment (P<0.05) (G). The level of γδT cells in peripheral blood decreased in the BMMSC group (P<0.05) (H). The expression of ALP (I) and TRAP (J) increased 12 months after BMMSC treatment, whereas the levels of IFN-γ (K) and IL-6 (L) decreased (*P<0.05; **P<0.01; ***P<0.001). IFN, interferon; TRAP, tartrate-resistant acid phosphatase.